Prestige BioPharma

Company snapshot

Prestige Biopharma Belgium is a biotech organization headquartered in EU. Primary therapeutic focus areas include HER2 Positive Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1), phase 1 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Prestige BioPharma. Not investment advice.

• What is Prestige BioPharma?

  Prestige Biopharma Belgium is a biotech organization headquartered in EU. Primary therapeutic focus areas include HER2 Positive Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials

• Is Prestige BioPharma publicly traded?

  Prestige BioPharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Prestige BioPharma develop or market?

  No drug profiles are currently linked to Prestige BioPharma. Pipeline programs may still list investigational assets.

• What are the latest developments for Prestige BioPharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Prestige BioPharma focus on?

  Prestige BioPharma focuses on HER2 Positive Breast Cancer based on our analysis of their pipeline programs and drug development activities.